VEEV Stock Recent News
VEEV LATEST HEADLINES
Veeva Systems VEEV is currently in its 17th Phase of the 18-phase Adhishthana Cycle, and despite what may appear as bullish structure on the weekly charts, the best move for investors right now is to stay away. Here's why.
Veeva Systems delivered a standout quarter, raising guidance and demonstrating accelerating growth, with Crossix and the company's Commercial Cloud, overall, driving strong revenue and margin outperformance. Despite macro and competitive risks, I see Veeva's competitive position strengthening, especially as migrations to Vault CRM and new AI offerings gain traction. Veeva AI, launching in December, is poised to boost growth and productivity, supporting my increased 3-year CAGR estimate to 20% and justifying the premium valuation.
Veeva Systems launches China Campaign Manager to boost pharma engagement with localized, compliant CRM-driven solutions.
Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date.
SSRM, VEEV and BAESY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 11, 2025.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
PROSY, EVR, VEEV, BAESY and SSUMY have been added to the Zacks Rank #1 (Strong Buy) List on June 11, 2025.
More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed PLEASANTON, Calif. , June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies.